Showing 6421-6430 of 10817 results for "".
- ECZTEND: Tralokinumab-ldrm Achieves Lasting Efficacy in AD Patientshttps://practicaldermatology.com/news/ecztend-tralokinumab-ldrm-achieves-lasting-efficacy-ad-patients/2468493/Final results presented at Fall Clinical 2024 from the ECZTEND study confirmed long-term safety and efficacy of tralokinumab-ldrm in adolescents and adults with moderate-to-severe atopic dermatitis (AD). The open-label, single-arm trial included 1,672 participants who transitioned from nin
- Details Revealed for Upcoming Phase 2 Study for New AD Drug from Apogeehttps://practicaldermatology.com/news/details-revealed-upcoming-phase-2-study-new-ad-drug-apogee/2468489/Apogee Therapeutics’ half-life-extended monoclonal antibody APG777 for atopic dermatitis was the subject of a poster presented by Dr. Emma Guttman-Yassky and others at the 44th Annual Fall Clinical Dermatology Conference. The poster detailed the design of the phase 2 APEX study. “IL
- Analysis: Lebrikizumab Viable Dupilumab Alternative for Moderate-to-Severe ADhttps://practicaldermatology.com/news/analysis-lebrikizumab-viable-dupilumab-alternative-moderate-severe-ad/2468484/Lebrikizumab is a viable alternative for patients with moderate-to-severe atopic dermatitis (AD) who discontinue dupilumab due to inadequate response, inability to tolerate the drug, or other reasons, according to a new study presented at the Fall Clini
- ADORING 3: Tapinarof Cream Maintains AD Clearance for 80 Days Post-Treatmenthttps://practicaldermatology.com/news/adoring-3-tapinarof-cream-maintains-ad-clearance-80-days-post-treatment/2468482/Results from the ADORING 3 long-term extension study showed that VTAMA® (tapinarof) cream, 1% achieved complete skin clearance in atopic dermatitis (AD) patients as young as two years old, maintaining clear or nearly clear skin for an average of 80 days post-treatment. The 48-week study, p
- Dupilumab Improves Chronic Spontaneous Urticaria Symptomshttps://practicaldermatology.com/news/dupixent-improves-chronic-spontaneous-urticaria-symptoms/2468471/Dupixent® (dupilumab) significantly reduced itch and hive activity in patients with chronic spontaneous urticaria, according to phase 3 trial data presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2024 Annual Scientific Meeting in Boston, Massachusetts. In a pre
- READY-4: Sustained and Safety Efficacy of RelabotulinumtoxinAhttps://practicaldermatology.com/news/ready-4-sustained-and-safety-efficacy-relabotulinumtoxina/2468443/New results from the phase III READY-4 trial presented at the 2024 ASDS Annual Meeting demonstrate the long-term safety and sustained efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™) for the treatment of moderate-to-severe frown lines and crow’s feet. The multicenter, open-label REA
- JOYA Launches Skin Cancer Prevention, Anti-Aging Employee Benefit Platformhttps://practicaldermatology.com/news/joya-launches-skin-cancer-prevention-anti-aging-employee-benefit-platform/2468435/JOYA, the first employee skin health and wellness benefit platform, announced its emergence from stealth mode with $5 million in seed funding from LUX Capital, Mosaic General Partnership, Arsama Trust, and Joyance Partners. The funding will support team expansion, product development, mar
- ZORYVE Foam Approved in Canada for Seborrheic Dermatitishttps://practicaldermatology.com/news/zoryve-foam-approved-canada-seborrheic-dermatitis/2468434/Health Canada has approved ZORYVE (roflumilast) foam 0.3% for treating seborrheic dermatitis in individuals aged nine and older, according to a press release from Arcutis. The approval makes ZORYVE the first new topical treatment for the condition approved in Canada in over 20 years. The a
- FDA Clears Accure Laser System for Acne Vulgarishttps://practicaldermatology.com/news/fda-clears-accure-laser-system-acne-vulgaris/2468432/The US Food and Drug Administration (FDA) cleared the Accure Laser System for the long-term treatment of patients with mild-to-severe inflammatory acne vulgaris, according to a press release from Accure Acne, Inc. "This achievement cannot be overstated," Acclure Acne co-founder, chairman o
- Study: R&R Complex Superior to Ceramide Moisturizer for Dermatoporosishttps://practicaldermatology.com/news/study-rr-complex-superior-ceramide-moisturizer-dermatoporosis/2468413/Results from a split-arm study suggest that use of a new product (ReFORM & RePAIR COMPLEX with TriHex Technology® [R&R]) resulted in more skin improvements than a ceramide moisturizer in patients with dermatoporosis (DP). Conducted over 24 weeks, the trial included 38 participants